相似文献
1
Ras oncogenes: split personalities.
Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31. doi: 10.1038/nrm2438.
2
The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.
J Biol Chem. 2004 Aug 6;279(32):33480-91. doi: 10.1074/jbc.M404058200. Epub 2004 Jun 4.
3
Ras-induced cellular events (review).
Mol Membr Biol. 2000 Apr-Jun;17(2):65-73. doi: 10.1080/09687680050117093.
4
Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth.
Oncogene. 1999 Jul 1;18(26):3831-45. doi: 10.1038/sj.onc.1202758.
5
Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.
Angew Chem Int Ed Engl. 2004 Jan 16;43(4):454-8. doi: 10.1002/anie.200353089.
6
Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Oncogene. 2000 Sep 28;19(41):4685-94. doi: 10.1038/sj.onc.1203836.
7
R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells.
Oncogene. 2000 Apr 13;19(16):2014-22. doi: 10.1038/sj.onc.1203530.
8
Transcriptional regulation of the TATA-binding protein by Ras cellular signaling.
Mol Cell Biol. 2000 Jul;20(14):5000-9. doi: 10.1128/MCB.20.14.5000-5009.2000.
9
Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-RasV12.
Mol Cell Biol. 2004 Sep;24(17):7380-91. doi: 10.1128/MCB.24.17.7380-7391.2004.
10
The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.
Science. 1997 Jul 18;277(5324):333-8. doi: 10.1126/science.277.5324.333.
引用本文的文献
1
RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of Genes and Ras Proteins in Housekeeping and Tumorigenesis.
Biology (Basel). 2025 Jul 25;14(8):936. doi: 10.3390/biology14080936.
2
Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and Therapeutic Target Identification.
Cancer Genomics Proteomics. 2025 Sep-Oct;22(5):654-682. doi: 10.21873/cgp.20528.
3
Exploring the metabolic signaling network of GFPT in cancer.
Cell Death Discov. 2025 Aug 19;11(1):388. doi: 10.1038/s41420-025-02687-3.
4
Literature review of advances and challenges in mutant non-small cell lung cancer.
Transl Lung Cancer Res. 2025 Jul 31;14(7):2799-2820. doi: 10.21037/tlcr-2025-164. Epub 2025 Jul 15.
5
FEZF1-AS1 drives autophagy-mediated progression of colon cancer and reduces chemosensitivity through inhabiting the PI3K/AKT/mTOR signaling pathway.
Front Genet. 2025 Jul 24;16:1514205. doi: 10.3389/fgene.2025.1514205. eCollection 2025.
6
EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.
Cell Oncol (Dordr). 2025 Jul 10. doi: 10.1007/s13402-025-01075-4.
7
Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types.
Sci Rep. 2025 Jul 2;15(1):23675. doi: 10.1038/s41598-025-94084-0.
8
Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review.
Discov Oncol. 2025 Jun 7;16(1):1029. doi: 10.1007/s12672-025-02783-x.
9
Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.
Front Immunol. 2025 Apr 15;16:1509173. doi: 10.3389/fimmu.2025.1509173. eCollection 2025.
10
The role of autophagy in cancer: from molecular mechanism to therapeutic window.
Front Immunol. 2025 Apr 3;16:1528230. doi: 10.3389/fimmu.2025.1528230. eCollection 2025.
本文引用的文献
1
RIN1 is a breast tumor suppressor gene.
Cancer Res. 2007 Dec 15;67(24):11510-6. doi: 10.1158/0008-5472.CAN-07-1147.
2
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
Cell. 2007 Jun 1;129(5):957-68. doi: 10.1016/j.cell.2007.03.051.
3
PRAK is essential for ras-induced senescence and tumor suppression.
Cell. 2007 Jan 26;128(2):295-308. doi: 10.1016/j.cell.2006.11.050.
4
The role of Shp2 (PTPN11) in cancer.
Curr Opin Genet Dev. 2007 Feb;17(1):23-30. doi: 10.1016/j.gde.2006.12.011. Epub 2007 Jan 16.
5
Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
Nat Genet. 2007 Jan;39(1):70-4. doi: 10.1038/ng1926. Epub 2006 Dec 3.
6
Reactive oxygen species-induced activation of the MAP kinase signaling pathways.
Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1775-89. doi: 10.1089/ars.2006.8.1775.
7
The neurofibromin GAP-related domain rescues endothelial but not neural crest development in Nf1 mice.
J Clin Invest. 2006 Sep;116(9):2378-84. doi: 10.1172/JCI28341. Epub 2006 Aug 10.
8
The cardiofaciocutaneous syndrome.
J Med Genet. 2006 Nov;43(11):833-42. doi: 10.1136/jmg.2006.042796. Epub 2006 Jul 6.
9
Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras.
J Lipid Res. 2006 May;47(5):883-91. doi: 10.1194/jlr.R600004-JLR200. Epub 2006 Mar 16.
10
Differential modification of Ras proteins by ubiquitination.
Mol Cell. 2006 Mar 3;21(5):679-87. doi: 10.1016/j.molcel.2006.02.011.
Zotero 插件